Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMRG0A3)

Drug Name

ARQ 531 Drug Info

Synonyms

JSFCZQSJQXFJDS-QAPCUYQASA-N; UNII-JTZ51LIXN4; JTZ51LIXN4; 2095393-15-8; ARQ-531; ARQ531; SCHEMBL18770934; SCHEMBL18756744; EX-A2727; BCP29029; HY-112215; CS-0044154; HRA; (2-Chloro-4-phenoxyphenyl)(4-(((3R,6S)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)amino)-7H-pyrrolo(2,3-d)pyrimidin-5-yl)methanone; 1,5-anhydro-2-{[5-(2-chloro-4-phenoxybenzene-1-carbonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino}-2,3,4-trideoxy-D-erythro-hexitol

Indication

Disease Entry	ICD 11	Status	REF
Hematologic tumour	2B33.Y	Phase 2	[1]

Cross-matching ID

PubChem CID: 129045720
CAS Number: CAS 2095393-15-8
TTD Drug ID: DMRG0A3

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Tyrosine-protein kinase BTK (ATK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ibrutinib	DMHZCPO	Mantle cell lymphoma	2A85.5	Approved	[3]
Acalabrutinib	DM7GCVW	leukaemia	2A60-2B33	Approved	[4]
Zanubrutinib	DMJWRQP	Mantle cell lymphoma	2A85.5	Approved	[5]
Pirtobrutinib	DMRG1X3	Non-hodgkin lymphoma	2B33.5	Approved	[6]
GDC-0853	DMBEL3Q	Multiple sclerosis	8A40	Phase 3	[7]
ICP-022	DMU72KL	Chronic lymphocytic leukaemia	2A82.0	Phase 3	[8]
Tolebrutinib	DML19V6	Multiple sclerosis	8A40	Phase 3	[9]
CC-292	DMJR9H0	Chronic lymphocytic leukaemia	2A82.0	Phase 2	[10]
BMS-986142	DMZB8AJ	Rheumatoid arthritis	FA20	Phase 2	[7]
LOU064	DME8O5K	Chronic idiopathic urticaria	EB00.1	Phase 2	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tyrosine-protein kinase BTK (ATK)	TTGM6VW	BTK_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04728893) Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies (MK-1026-003). U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1948).
4	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
5	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
6	Targeting BTK in CLL: Beyond Ibrutinib. Curr Hematol Malig Rep. 2019 Jun;14(3):197-205.
7	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8	Clinical pipeline report, company report or official report of InnoCare Pharma.
9	Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2021 Sep;20(9):729-738.
10	Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans. J Pharmacol Exp Ther. 2013 Aug;346(2):219-28.
11	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)